177 related articles for article (PubMed ID: 35325102)
1. Influence of atrial fibrillation on efficacy and safety of omecamtiv mecarbil in heart failure: the GALACTIC-HF trial.
Solomon SD; Claggett BL; Miao ZM; Diaz R; Felker GM; McMurray JJV; Metra M; Corbalan R; Filippatos G; Goudev AR; Mareev V; Serpytis P; Suter T; Yilmaz MB; Zannad F; Kupfer S; Heitner SB; Malik FI; Teerlink JR
Eur Heart J; 2022 Jun; 43(23):2212-2220. PubMed ID: 35325102
[TBL] [Abstract][Full Text] [Related]
2. Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction: Rationale and Design of GALACTIC-HF.
Teerlink JR; Diaz R; Felker GM; McMurray JJV; Metra M; Solomon SD; Legg JC; Büchele G; Varin C; Kurtz CE; Malik FI; Honarpour N
JACC Heart Fail; 2020 Apr; 8(4):329-340. PubMed ID: 32035892
[TBL] [Abstract][Full Text] [Related]
3. Assessment of Omecamtiv Mecarbil for the Treatment of Patients With Severe Heart Failure: A Post Hoc Analysis of Data From the GALACTIC-HF Randomized Clinical Trial.
Felker GM; Solomon SD; Claggett B; Diaz R; McMurray JJV; Metra M; Anand I; Crespo-Leiro MG; Dahlström U; Goncalvesova E; Howlett JG; MacDonald P; Parkhomenko A; Tomcsányi J; Abbasi SA; Heitner SB; Hucko T; Kupfer S; Malik FI; Teerlink JR
JAMA Cardiol; 2022 Jan; 7(1):26-34. PubMed ID: 34643642
[TBL] [Abstract][Full Text] [Related]
4. Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials.
Teerlink JR; Diaz R; Felker GM; McMurray JJV; Metra M; Solomon SD; Adams KF; Anand I; Arias-Mendoza A; Biering-Sørensen T; Böhm M; Bonderman D; Cleland JGF; Corbalan R; Crespo-Leiro MG; Dahlström U; Echeverria Correa LE; Fang JC; Filippatos G; Fonseca C; Goncalvesova E; Goudev AR; Howlett JG; Lanfear DE; Lund M; Macdonald P; Mareev V; Momomura SI; O'Meara E; Parkhomenko A; Ponikowski P; Ramires FJA; Serpytis P; Sliwa K; Spinar J; Suter TM; Tomcsanyi J; Vandekerckhove H; Vinereanu D; Voors AA; Yilmaz MB; Zannad F; Sharpsten L; Legg JC; Abbasi SA; Varin C; Malik FI; Kurtz CE;
Eur J Heart Fail; 2020 Nov; 22(11):2160-2171. PubMed ID: 32985088
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of omecamtiv mecarbil in heart failure with reduced ejection fraction according to N-terminal pro-B-type natriuretic peptide level: insights from the GALACTIC-HF trial.
Docherty KF; McMurray JJV; Claggett BL; Miao ZM; Adams KF; Arias-Mendoza A; Cleland JGF; Diaz R; Echeverria Correa LE; Felker GM; Fonseca C; Li J; Metra M; Sliwa-Hahnle K; Solomon SD; Vandekerckhove HJ; Vinereanu D; Voors AA; Heitner SB; Kupfer S; Malik FI; Meng L; Teerlink JR
Eur J Heart Fail; 2023 Feb; 25(2):248-259. PubMed ID: 36597719
[TBL] [Abstract][Full Text] [Related]
6. Effect of Ejection Fraction on Clinical Outcomes in Patients Treated With Omecamtiv Mecarbil in GALACTIC-HF.
Teerlink JR; Diaz R; Felker GM; McMurray JJV; Metra M; Solomon SD; Biering-Sørensen T; Böhm M; Bonderman D; Fang JC; Lanfear DE; Lund M; Momomura SI; O'Meara E; Ponikowski P; Spinar J; Flores-Arredondo JH; Claggett BL; Heitner SB; Kupfer S; Abbasi SA; Malik FI;
J Am Coll Cardiol; 2021 Jul; 78(2):97-108. PubMed ID: 34015475
[TBL] [Abstract][Full Text] [Related]
7. Effect of Omecamtiv Mecarbil on Exercise Capacity in Chronic Heart Failure With Reduced Ejection Fraction: The METEORIC-HF Randomized Clinical Trial.
Lewis GD; Voors AA; Cohen-Solal A; Metra M; Whellan DJ; Ezekowitz JA; Böhm M; Teerlink JR; Docherty KF; Lopes RD; Divanji PH; Heitner SB; Kupfer S; Malik FI; Meng L; Wohltman A; Felker GM
JAMA; 2022 Jul; 328(3):259-269. PubMed ID: 35852527
[TBL] [Abstract][Full Text] [Related]
8. Sex Differences in Heart Failure With Reduced Ejection Fraction in the GALACTIC-HF Trial.
Pabon M; Cunningham J; Claggett B; Felker GM; McMurray JJV; Metra M; Diaz R; Wang X; Arias-Mendoza A; Bonderman D; Crespo-Leiro M; Fonseca C; Goncalvesova E; Lund M; O'Meara E; Sliwa-Hahnle K; Malik FI; Solomon SD; Teerlink JR;
JACC Heart Fail; 2023 Dec; 11(12):1729-1738. PubMed ID: 37831045
[TBL] [Abstract][Full Text] [Related]
9. Omecamtiv Mecarbil in Black Patients With Heart Failure and Reduced Ejection Fraction: Insights From GALACTIC-HF.
Lanfear DE; Njoroge JN; Adams KF; Anand I; Fang JC; Ramires F; Sliwa-Hahnle K; Badat A; Burgess L; Gorodeski EZ; Williams C; Diaz R; Felker GM; McMurray JJV; Metra M; Solomon S; Miao ZM; Claggett BL; Heitner SB; Kupfer S; Malik FI; Teerlink JR
JACC Heart Fail; 2023 May; 11(5):569-579. PubMed ID: 36881396
[TBL] [Abstract][Full Text] [Related]
10. Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure.
Teerlink JR; Diaz R; Felker GM; McMurray JJV; Metra M; Solomon SD; Adams KF; Anand I; Arias-Mendoza A; Biering-Sørensen T; Böhm M; Bonderman D; Cleland JGF; Corbalan R; Crespo-Leiro MG; Dahlström U; Echeverria LE; Fang JC; Filippatos G; Fonseca C; Goncalvesova E; Goudev AR; Howlett JG; Lanfear DE; Li J; Lund M; Macdonald P; Mareev V; Momomura SI; O'Meara E; Parkhomenko A; Ponikowski P; Ramires FJA; Serpytis P; Sliwa K; Spinar J; Suter TM; Tomcsanyi J; Vandekerckhove H; Vinereanu D; Voors AA; Yilmaz MB; Zannad F; Sharpsten L; Legg JC; Varin C; Honarpour N; Abbasi SA; Malik FI; Kurtz CE;
N Engl J Med; 2021 Jan; 384(2):105-116. PubMed ID: 33185990
[TBL] [Abstract][Full Text] [Related]
11. Cardiac Troponin and Treatment Effects of Omecamtiv Mecarbil: Results From the GALACTIC-HF Study.
Felker GM; Solomon SD; Metra M; Mcmurray JJV; Diaz R; Claggett B; Lanfear DE; Vandekerckhove H; Biering-Sørensen T; Lopes RD; Arias-Mendoza A; Momomura SI; Corbalan R; Ramires FJA; Zannad F; Heitner SB; Divanji PH; Kupfer S; Malik FI; Teerlink JR
J Card Fail; 2024 Jun; 30(6):755-763. PubMed ID: 38215932
[TBL] [Abstract][Full Text] [Related]
12. The Effect of Omecamtiv Mecarbil in Hospitalized Patients as Compared With Outpatients With HFrEF: An Analysis of GALACTIC-HF.
Docherty KF; McMurray JJV; Diaz R; Felker GM; Metra M; Solomon SD; Adams KF; Böhm M; Brinkley DM; Echeverria LE; Goudev AR; Howlett JG; Lund M; Ponikowski P; Yilmaz MB; Zannad F; Claggett BL; Miao ZM; Abbasi SA; Divanji P; Heitner SB; Kupfer S; Malik FI; Teerlink JR
J Card Fail; 2024 Jan; 30(1):26-35. PubMed ID: 37683911
[TBL] [Abstract][Full Text] [Related]
13. [CLINICAL EFFICACY OF A REPRESENTATIVE OF A NEW CLASS OF INOTROPIC AGENTS - THE DIRECT ACTIVATOR OF MYOSIN OF CARDIOMYOCYTES OMECAMTIV MECARBIL IN HEART FAILURE WITH A REDUCED EJECTION FRACTION].
Kravchenko I; Rudyk I; Medentseva O
Georgian Med News; 2021 Sep; (318):165-171. PubMed ID: 34628401
[TBL] [Abstract][Full Text] [Related]
14. Effects of omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: the GALACTIC-HF trial.
Metra M; Pagnesi M; Claggett BL; Díaz R; Felker GM; McMurray JJV; Solomon SD; Bonderman D; Fang JC; Fonseca C; Goncalvesova E; Howlett JG; Li J; O'Meara E; Miao ZM; Abbasi SA; Heitner SB; Kupfer S; Malik FI; Teerlink JR
Eur Heart J; 2022 Dec; 43(48):5006-5016. PubMed ID: 35675469
[TBL] [Abstract][Full Text] [Related]
15. Tricuspid Regurgitation and Clinical Outcomes in Heart Failure With Reduced Ejection Fraction.
Adamo M; Metra M; Claggett BL; Miao ZM; Diaz R; Felker GM; McMurray JJV; Solomon SD; Biering-Sørensen T; Divanji PH; Heitner SB; Kupfer S; Malik FI; Teerlink JR;
JACC Heart Fail; 2024 Mar; 12(3):552-563. PubMed ID: 38300212
[TBL] [Abstract][Full Text] [Related]
16. Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial.
Teerlink JR; Felker GM; McMurray JJ; Solomon SD; Adams KF; Cleland JG; Ezekowitz JA; Goudev A; Macdonald P; Metra M; Mitrovic V; Ponikowski P; Serpytis P; Spinar J; Tomcsányi J; Vandekerckhove HJ; Voors AA; Monsalvo ML; Johnston J; Malik FI; Honarpour N;
Lancet; 2016 Dec; 388(10062):2895-2903. PubMed ID: 27914656
[TBL] [Abstract][Full Text] [Related]
17. Omecamtiv mecarbil: a new cardiac myosin activator for the treatment of heart failure.
Liu LC; Dorhout B; van der Meer P; Teerlink JR; Voors AA
Expert Opin Investig Drugs; 2016; 25(1):117-27. PubMed ID: 26587768
[TBL] [Abstract][Full Text] [Related]
18. Cardiac myosin activators for heart failure therapy: focus on omecamtiv mecarbil.
Kaplinsky E; Mallarkey G
Drugs Context; 2018; 7():212518. PubMed ID: 29707029
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of omecamtiv mecarbil for heart failure: A systematic review and meta-analysis.
Alqatati F; Elbahnasawy M; Bugazia S; Ragab KM; Elsnhory AB; Shehata M; Elsayed SM; Fathy MA; Nourelden AZ
Indian Heart J; 2022; 74(3):155-162. PubMed ID: 35301008
[TBL] [Abstract][Full Text] [Related]
20. Population Pharmacokinetic Properties of Omecamtiv Mecarbil in Healthy Subjects and Patients With Heart Failure With Reduced Ejection Fraction.
Chen PW; Trivedi A; Lee E; Dutta S; Ahamadi M
J Cardiovasc Pharmacol; 2022 Apr; 79(4):539-548. PubMed ID: 34983909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
